Nicole Fett1, Kevin Haynes2, Kathleen Joy Propert2, David J Margolis3. 1. Philadelphia Department of Veterans Affairs Medical Center, Philadelphia, Pennsylvania; Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania. Electronic address: fett@ohsu.edu. 2. Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Center for Pharmacoepidermiology Research and Training, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. 3. Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.
Abstract
BACKGROUND: The incidence of malignancy in patients with chronic pruritus and nondiseased skin is unknown. OBJECTIVE: We sought to assess the hazard ratio (HR) of incident overall malignancy and incident malignancy by subtype in patients with chronic pruritus during the 5 years after diagnosis. METHODS: A population-based cohort study was performed in the Health Improvement Network. In all, 8744 patients with chronic pruritus were matched with 31,580 patients without chronic pruritus based on sex, age, and practice. Primary outcomes were HR of incident malignancy and HR of malignancy subtypes. RESULTS: The fully adjusted HR for incident malignancy in patients with chronic pruritus was 1.14 (95% confidence interval 0.98-1.33). The fully adjusted HR for incident hematologic malignancy and incident bile duct malignancy in patients with chronic pruritus was 2.02 (95% confidence interval 1.48-2.75) and 3.73 (95% confidence interval 1.55-8.97), respectively. The incidence of hematologic malignancy and cholangiocarcinoma in patients with chronic pruritus was 0.0016 and 0.0003 per person-year, respectively. LIMITATIONS: Potential for misclassification and detection biases is a limitation. CONCLUSIONS: Chronic pruritus without concomitant skin changes is a risk factor for having undiagnosed hematologic and bile duct malignancies, but not other malignancies. The overall incidence of these malignancies in patients with chronic pruritus is very low.
BACKGROUND: The incidence of malignancy in patients with chronic pruritus and nondiseased skin is unknown. OBJECTIVE: We sought to assess the hazard ratio (HR) of incident overall malignancy and incident malignancy by subtype in patients with chronic pruritus during the 5 years after diagnosis. METHODS: A population-based cohort study was performed in the Health Improvement Network. In all, 8744 patients with chronic pruritus were matched with 31,580 patients without chronic pruritus based on sex, age, and practice. Primary outcomes were HR of incident malignancy and HR of malignancy subtypes. RESULTS: The fully adjusted HR for incident malignancy in patients with chronic pruritus was 1.14 (95% confidence interval 0.98-1.33). The fully adjusted HR for incident hematologic malignancy and incident bile duct malignancy in patients with chronic pruritus was 2.02 (95% confidence interval 1.48-2.75) and 3.73 (95% confidence interval 1.55-8.97), respectively. The incidence of hematologic malignancy and cholangiocarcinoma in patients with chronic pruritus was 0.0016 and 0.0003 per person-year, respectively. LIMITATIONS: Potential for misclassification and detection biases is a limitation. CONCLUSIONS:Chronic pruritus without concomitant skin changes is a risk factor for having undiagnosed hematologic and bile duct malignancies, but not other malignancies. The overall incidence of these malignancies in patients with chronic pruritus is very low.
Authors: Claudia D Furtado; Diego A Aguirre; Claude B Sirlin; David Dang; Stephan K Stamato; Patrick Lee; Farhad Sani; Michelle A Brown; David L Levin; Giovanna Casola Journal: Radiology Date: 2005-09-16 Impact factor: 11.105
Authors: A Nakeeb; H A Pitt; T A Sohn; J Coleman; R A Abrams; S Piantadosi; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron Journal: Ann Surg Date: 1996-10 Impact factor: 12.969
Authors: Peter C A Jacobs; Willem P Th M Mali; Diederick E Grobbee; Yolanda van der Graaf Journal: J Comput Assist Tomogr Date: 2008 Mar-Apr Impact factor: 1.826
Authors: M Elle Saine; Dena M Carbonari; Craig W Newcomb; Melissa S Nezamzadeh; Kevin Haynes; Jason A Roy; Serena Cardillo; Sean Hennessy; Crystal N Holick; Daina B Esposito; Arlene M Gallagher; Harshvinder Bhullar; Brian L Strom; Vincent Lo Re Journal: BMC Pharmacol Toxicol Date: 2015-04-02 Impact factor: 2.483
Authors: Vincent Lo Re; Dena M Carbonari; M Elle Saine; Craig W Newcomb; Jason A Roy; Qing Liu; Qufei Wu; Serena Cardillo; Kevin Haynes; Stephen E Kimmel; Peter P Reese; David J Margolis; Andrea J Apter; K Rajender Reddy; Sean Hennessy; Harshvinder Bhullar; Arlene M Gallagher; Daina B Esposito; Brian L Strom Journal: BMJ Open Diabetes Res Care Date: 2017-07-31